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Background  :  The  objectives  of  this  study  were  to  determine  the  incidence,  outcome  and  risk  factors  for  HBV 
reactivation  in  HBsAg  positive  breast  cancer  patients  while  on  anthracycline  -based  adjuvant  chemotherapy. 
Methods  :  We  retrospectively  reviewed  the  records  of  2,431  patients  with  early  breast  cancer  who  received  adjuvant 
chemotherapy  from  March  2001  to  December  2005.  Among  these  patients,  111  HBsAg  positive  women  were  enrolled 
in  this  study. 
Results  :  Thirty-seven  patients  (33.3%)  developed  acute  hepatitis,  of  which  23  (20.7%)  were  related  to  HBV 
reactivation.  Univariate  analysis  showed  that  an  age  ≥47  years  (p=0.034)  and  abnormal  sonographic  findings  such  as 
a  fatty  liver  or  cirrhotic  changes  (p=0.034)  were  associated  with  HBV  reactivation.  However,  an  HBeAg  positive  status 
and  the  use  of  corticosteroids  were  not.  Multivariate  analysis  found  that  no  clinical  factors  could  predict  HBV 
reactivation  during  chemotherapy.  All  23  patients  who  developed  HBV  reactivation  received  lamivudine  as  a  therapeutic 
measure  at  the  time  of  HBV  reactivation.  Despite  the  use  of  lamivudine,  disruption  in  the  chemotherapy  protocol 
occurred  in  18  patients  (78.3%)  and  14  of  these  patients  had  premature  termination  of  their  chemotherapy. 
Conclusions  :  HBV  reactivation  occurred  in  a  significant  proportion  of  HBsAg  positive  patients  during  adjuvant 
anthracycline-based  chemotherapy.  Once  hepatitis  developed,  most  patients  could  not  finish  the  chemotherapy  as 
planned  despite  lamivudine  treatment.  Until  the  risk  factors  for  reactivation  are  clearly  identified,  HbsAg-positive  patients 
should  begin  prophylactic  antiviral  treatment  before  initiating  chemotherapy.
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INTRODUCTION
Korea  is  recognized  as  an  endemic  area  of  hepatitis  B  virus 
(HBV)  infection,  with  an  HBsAg  prevalence  of  5.1%  in  men  and 
4.1%  in  women
1).  HBV  reactivation  frequently  occurs  in  cancer 
patients  undergoing  chemotherapy  who  are  HBV  carriers
2-4). 
HBV  reactivation  is  characterized  by  an  increased  serum  HBV 
DNA  level,  abnormal  liver  function  tests  and  clinical  hepatitis. 
The  severity  of  the  condition  ranges  from  anicteric  hepatitis, 
which  may  recover  spontaneously,  to  fatal  hepatic  failure
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Figure  1.  Summary  of  enrollment  of  patients.
The  mechanism  of  HBV  reactivation  during  chemotherapy 
may  be  associated  with  the  suppression  of  the  normal 
immunological  responses  to  HBV,  leading  to  enhanced  viral 
replication  and  widespread  infection  of  hepatocytes
6, 7).  When 
the  cancer  chemotherapy  is  discontinued,  immune  competence 
is  restored  and  infected  hepatocytes  are  rapidly  destroyed. 
In  reports  from  China  and  Greece,  the  risk  of 
chemotherapy-induced  HBV  reactivation  was  reported  to  range 
from  14%  to  72%
8-11).  Lamivudine,  a  cyclic  nucleoside  analogue, 
is  effective  in  suppressing  HBV  DNA,  normalizing  liver  enzymes 
and  improving  the  histology  in  both  HBeAg-positive  and 
-negative/HBV-DNA  positive  patients.  This  effect  suggests  that 
pophylactic  antiviral  therapy  might  reduce  the  risk  of  HBV 
reactivation  and  prevent  the  associated  complications
12, 13). 
However,  these  previous  studies,  were  limited  by  their  small 
sample  size,  heterogeneity  in  the  tumor  type  and  varying 
chemotherapy  regimens
10, 11).  The  immunosuppressive  effects  of 
adjuvant  chemotherapy  for  the  treatment  of  patients  with  breast 
cancer  are  not  considered  severe
14).  The  optimal  duration  of 
prophylactic  lamivudine  therapy  is  uncertain.  Use  of  this 
medication  must  take  into  consideration  the  potential  emergence 
of  the  lamivudine-  resistant  HBV  strain,  the  so-called  YMDD 
mutation  that  can  develop  during  lamivudine  prophylaxis
15, 16). 
Currently,  the  indications  for  prophylactic  therapy,  to  prevent 
HBV  reactivation  in  patients  receiving  adjuvant  chemotherapy, 
are  not  clear
17).
Although  Korea  is  an  endemic  area  for  chronic  HBV  infection, 
there  have  been  few  clinical  studies  on  the  reactivation  of  HBV 
during  treatment  with  chemotherapy  for  solid  tumors.  We 
therefore  retrospectively  assessed  the  incidence  of  HBV 
reactivation  and  hepatitis  in  HBsAg  positive  patients  who  were 
receiving  breast  adjuvant  chemotherapy  to  identify  the  risk 
factors  associated  with  HBV  reactivation. 
MATERIALS AND METHODS
Patients
A  review  of  the  Breast  Cancer  Adjuvant  Treatment  Registry 
at  the  Asan  Medical  Center  revealed  that  2,431  patients 
received  adjuvant  chemotherapy  from  August  2001  through 
December  2005.  Among  these  patients,  we  selected  those  who 
(1)  were  serologically  HBsAg  positive  before  adjuvant  chem-
otherapy;  (2)  received  anthracycline-based  chemotherapy  and 
(3)  had  adequate  liver  function  (liver  transaminase  levels  ≤3 
times  the  upper  normal  limit  and  serum  bilirubin  ≤1.5  mg/dL). 
We  excluded  patients  who  had  previously  received  anti-HBV 
therapy  (e.g.  lamivudine  or  interferon  alpha)  and  those  with 
decompensated  liver  function  at  screening  (prolonged 
prothrombin  time,  history  of  ascites,  hypoalbuminemia,  history  of 
ascites,  variceal  bleeding,  or  hepatic  encephalopathy).  Of  the 
2,431  patients,  120  were  HBsAg  seropositive.  After  excluding 
nine  patients  (2  men,  1  woman  who  was  receiving  lamivudine 
and  6  women  who  received  CMF  regimens),  111  patients  were 
included  in  this  study  (Figure  1).
Laboratory  studies  and  monitoring  for  HBV  reactivation
According  to  the  standard  admission  protocol  of  our  surgical 
department,  breast  cancer  patients  eligible  for  surgery  were 
screened  for  hepatitis-B  serology  (i.e.HBs  Ag,  anti-HBs  and 
antiHBc  IgG)  using  a  commercially  available  immunoassay  ( 
A6K-3
Ⓡ  RIA-IRMA  Immuno-RadioMetric  Assay;  Diasorin  Inc., 
Stillwater,  MN,  USA).  In  addition,  their  serum  protein,  albumin, 
bilirubin,  alkaline  phosphatase  (ALP),  aspartate  aminotransferase 
(AST),  alanine  aminotransferase  (ALT))  and  clotting  profile  were 
evaluated,  and  they  were  tested  for  the  HCV  antibody.  The 
HBeAg,  anti-HBe,  antiHBc  IgM,  and  serum  HBV  DNA  level 
were  also  studied  in  patients  who  were  HBsAg  positive.  The 
serum  HBV  DNA  was  quantitated  using  the  hybrid  capture 
assay  (Digene  Corp.,  Gaithersburg,  MD,  USA),  which  has  a  limit 
of  detection  of  1.4X10
5  copies/mL  (1pg  HBV  DNA=283,000 
copies  (～3X10
5  viral  genome  equivalents))
18).  Ultrasonographic 
examination  of  the  liver  was  performed  within  2  weeks  prior  to 
surgery. 
On  day  1  and  day  8  of  the  first  cycle  of  adjuvant  chem-
otherapy,  before  each  subsequent  cycle  and  4  weeks  after  the 
completion  of  chemotherapy,  all  patients  were  monitored  by 
testing  for  the  complete  blood  count,  renal  function  tests  and 
liver  function  tests,  and  assessment  of  their  clinical  signs  and 
symptoms.  When  a  patient  was  found  to  have  developed 
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No.  of  patients  (n=111) %
Age  (years)
    Median  (range)
Chemotherapy
    AC
    CAF
    AC  → T
Prechemotherapy  status,  median,  range
ALT  (IU/L)
    Total  bilirubin  (mg/dL)
Albumin  (g/dL)
Ultrasonography  of  liver
    Normal
    Fatty  liver
    Cirrhosis  /  Chronic  liver  disease
    Missing
Viral  marker  status
    HBeAg  positive
    HBeAb  positive
    Missing
Corticosteroid 
    Yes
    No
47  (23-68)
77
12
22
17  (6-69)
0.7  (0.3-1.3)
3.8  (2.9-4.3)
56
21
23
11
17
68
26
64
47
69.4
10.8
19.8
50.5
18.9
20.7
9.9
15.3
61.3
23.4
57.7
42.3
AC,  adriamycin  and  cyclophosphamide;  CAF,  cyclophosphamide,  adriamycin  and  5-FU;  AC→T,  AC  followed  by  paclitaxel
Table  1.  Patient  baseline  characteristics
anti-HBe  and  HBV  DNA  were  measured,  along  with  tests  for 
hepatitis  A,  hepatitis  C  and  the  antinuclear  factor.
Adjuvant  chemotherapy 
Patients  were  treated  with  anthracycline-based  chemotherapy 
regimens,  either  AC  (adriamycin  60  mg/m
2  and  cyclophospha-
mide  600  mg/m
2  iv  push  on  day  1  for  four  cycles),  CAF 
(cyclophosphamide  600  mg/m
2,  adriamycin  60  mg/m
2  and  5FU 
600  mg/m
2  iv  push  on  day  1  for  six  cycles),  or  four  cycles  of  AC 
followed  by  four  cycles  of  paclitaxel  175  mg/m
2  iv  infusion. 
Patients  with  ≥5  cm  sized  primary  tumors  or≥4  positive  nodes, 
and  patients  who  underwent  breast-conserving  operations  were 
treated  with  adjuvant  radiotherapy  after  chemotherapy.  Patients 
with  ER  or  PR  positive  tumors  were  treated  for  5  years  with 
tamoxifen  therapy  after  adjuvant  chemotherapy. 
Definitions  of  hepatitis  and  HBV  reactivation
The  severity  of  hepatic  dysfunction  was  defined  as  grade  1 
when  ALT  was  ≤2.5  X  upper  limit  of  normal  (ULN);  grade  2 
when  ALT  was  between  2.5  X  ULN  and  5  X  ULN;  grade  3 
when  ALT  was  between  5  X  ULN  and  20  X  ULN;  and  grade  4 
when  ALT  was  >  20  X  ULN.  Hepatitis  was  defined  as  ALT  ≥3 
X  ULN  or  a  >  100U/L  increase  over  baseline  (3).  Hepatitis 
attributable  to  HBV  reactivation  was  defined  as  a  positive 
seroconversion  from  negative  (serum  HBV  DNA  <  1.4X10
5 
copies/mL)  or  increase  of  serum  HBV  DNA  level  ≥2  X  baseline 
in  addition  to  the  development  of  hepatitis  as  defined  above
19). 
Icteric  hepatitis  was  defined  as  hepatitis  accompanied  by  a 
serum  bilirubin  two-fold  higher  than  the  reference  range  (<  1.2 
mg/dL).  Disruption  of  chemotherapy  treatment  was  defined  as 
either  premature  termination  or  a  delay  of  more  than  8  days 
between  cycles. 
Statistical  analysis  and  risk  factor  assessment 
Among  the  risk  factors  assessed  were  patient  age  (younger 
or  older  than  median  age),  HBeAg  status,  pattern  of  liver 
ultrasonography  (e.g.  fatty  liver/cirrhosis),  baseline  ALT  level, 
chemotherapeutic  regimen,  and  use  of  corticosteroids  during 
chemotherapy.  Association  of  these  factors  with  the  deve-
lopment  of  HBV  reactivation  was  determined  using  the 
2  test  or 
Fisher's  exact  test,  as  appropriate.  Two-tailed  p-values  of  ≤
0.05  were  regarded  as  significant.  All  calculations  were  performed 
using  SPSS  version  12.0  (SPSS  Inc.,  Chicago,  IL,  USA).
RESULTS
Baseline  characteristics 
All  111  patients  were  women;  their  median  age  was  47  years 
(range,  23-68  years),  and  they  received  a  median  of  five 
chemotherapy  cycles  (range,  1  to  8  cycles).  Of  the  111  HBsAg 
seropositive  patients,  77  (69.4%)  received  the  AC  (adriamycin/ 
cyclophosphamide)  regimen,  22  patients  (19.8%)  received  AC 
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No.  of  patients  (n=23)
Chemotherapy  (median  cycles  before  hepatitis)
    AC
    CAF
    AC  → T
Peak  ALT  (IU/L),  median,  range
Peak  bilirubin  (mg/dL),  median,  range
Peak  HBV  DNA  (×10
5  copies/mL),  median,  range
Hospitalization,  yes
Median  duration  of  hospitalization,  days
Disruption  of  chemotherapy
    Delayed
    Early  terminated
18  (3)
3  (4)
2  (4)
584  (127-2362)
1.1  (0.4-15.3)
  2.1×10
2  (9.3-8.4×10
4)
16
11  (5-40)
4 
14
AC,  adriamycin  and  cyclophosphamide;  CAF,  cyclophosphamide,  adriamycin  and  5-FU;  AC→ T,  AC  followed  by  paclitaxel
Table  2.  Morbidity  of  the  23  patients  who  developed  acute  hepatitis  related  to  HBV  reactivation  during  chemotherapy
Total
N=97
Patients  who  had  HBV 
reactivation  during 
chemotherapy  (N=23)
Patients  who  did  not  develop 
HBV  reactivation  during 
chemotherapy  (N=74)
p  value
Age
  <  47
  ≥47
Corticosteroid
  Yes
  No
Viral  marker  status
  HBeAg  positive
  HBeAb  positive
  Missing
Ultrasonography  of  liver
  Normal
  Fatty  liver/cirrhosis
  Missing
Chemotherapy
  AC
  CAF
  AC  → T
44
53
59
38
17
55
25
48
38
11
67
12
18
6
17
11
12
4
19
0
7
13
3
17
4
2
38
36
48
26
13
36
25
41
25
8
50
8
16
0.034
0.144
0.554
0.034
0.317
AC,  adriamycin  and  cyclophosphamide;  CAF,  cyclophosphamide,  adriamycin  and  5-FU;  AC→ T,  AC  followed  by  paclitaxel
Table  3.  Comparison  between  patients  with  and  without  ‘HBV  reactivation' 
received  the  CAF  (cyclophosphamide/adriamycin/fluorouracil) 
regimen.  Five  patients  had  grade  1  hepatic  dysfunction  at 
baseline  and  all  others  had  normal  liver  function.  Fifty-six 
patients  showed  normal  patterns  on  hepatic  ultrasonography, 
whereas  44  (39.6%)  had  abnormal  sonographic  features  (fatty 
liver  or  cirrhotic  change).  Seventeen  patients  (15.3%)  were 
HBeAg  seropositive.  Sixty-four  patients  (55.7%)  were  treated 
with  corticosteroids  for  its  antiemetic  effect  and  as  a  paclitaxel 
premedication  (Table  1). 
Hepatitis  due  to  HBV  exacerbation
Sixty-two  patients  (60.4%)  with  normal  baseline  liver  function 
experienced  one  or  more  episodes  of  grade  1  hepatic 
dysfunction  during  adjuvant  chemotherapy.  Thirty-seven  patients 
(33.3%)  developed  acute  hepatitis,  with  23  (20.7%)  considered  to 
be  due  to  HBV  reactivation.  Of  these  23,  12  patients  (52.2%) 
developed  icteric  hepatitis.  The  severity  of  hepatitis  attributable 
to  HBV  reactivation  was  grade  2  in  1  patient,  grade  3  in  9 
patients  and  grade  4  in  13  patients.  The  time  from  the 
identification  of  an  abnormal  (grade  1)  liver  function  test  to  the 
detection  of  HBV  DNA  was  a  median  of  22  days  (range,  0-29). 
The  median  number  of  cycles  of  chemotherapy  administered 
before  the  detection  of  hepatitis  was  three  (range,  2-6).  Seven 
patients  had  HBV  reactivation  right  after  the  last  cycle  of 
planned  chemotherapy.  The  median  HBV  DNA  level  in  these  23 
patients  was  2.1×10
7  copies/mL  (Table  2).  Lamivudine  treatment 
was  initiated  after  a  median  of  7  days  from  the  detection  of 
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Hepatitis  due  to  undetermined  causes
Fourteen  patients  developed  hepatitis  from  unknown  causes; 
the  HBV  DNA  was  not  detected  in  any  of  these  patients.  In  all 
14  patients,  the  tests  for  the  diagnosis  of  hepatitis  A  and  C 
were  negative.  One  patient  had  a  history  of  taking  Ginseng  and 
another  had  taken  acetaminophen  for  7  days.  The  severity  of 
hepatitis  was  grade  2  in  6  patients,  grade  3  in  4  patients,  and 
grade  4  in  4  patients.  None  of  these  patients  had  icteric 
hepatitis.  These  patients  received  a  median  of  4  cycles  of 
chemotherapy  (range,  1-5  cycles)  before  the  detection  of 
hepatitis. 
Clinical  outcomes  and  impact  on  chemotherapy
The  23  patients  who  developed  acute  hepatitis  related  to 
HBV  reactivation  had  a  baseline  ALT  level  before  chemotherapy 
of  18  IU/L  (range  7-38  IU/L).  Their  peak  ALT  while  on 
chemotherapy  was  584  IU/L  (range  127-2362  IU/L).  Sixteen 
patients  (70%)  were  hospitalized  for  a  median  11  days  (range 
5-40  days).  All  23  patients  were  treated  with  lamivudine  for  a 
median  of  209  days  (range  52  to  385  days).  The  hepatic 
dysfunction  was  normalized  within  a  median  39  days  (range, 
7-162  days)  in  all  patients.  However,  the  chemotherapy  was 
disrupted  in  18  patients  (78.3%);  the  chemotherapy  was  delayed 
in  4  patients  (17.4%)  and  terminated  early  in  14  (60.9%)  (Table 
2).  In  patients  who  had  their  chemotherapy  terminated  early,  the 
hepatic  dysfunction  normalized  within  a  median  of  51  days 
(range,  23-162  days).  Among  the  14  patients  who  had  acute 
hepatitis  of  unknown  cause,  only  one  patient  was  hospitalized 
for  5  days,  whereas  disruption  of  the  chemotherapy  occurred  in 
five  patients.
Risk  factor  assessments
Univariate  analysis  showed  that,  patients  ≥47  years  old 
(p=0.034)  and  those  with  fatty  liver  or  cirrhotic  changes  on 
hepatic  ultrasonography  (p=0.034)  were  at  greater  risk  for  the 
development  of  hepatitis  related  to  HBV  reactivation  (Table  3). 
However,  neither  HBeAg  positivity  nor  the  use  of  corticosteroids 
was  significantly  correlated  with  HBV  reactivation.  The 
multivariate  analysis  identified  no  clinical  factor  that  could  predict 
the  development  of  HBV  reactivation. 
DISCUSSION
HBV  reactivation  is  common  in  patients  with  malignancies, 
especially  during  chemotherapy.  Although  prophylactic  lamivu-
dine  before  chemotherapy  has  been  recommended  for  patients 
with  hematological  malignancies,  little  is  known  about  the 
frequency,  risk  factors  and  prophylactic  use  of  lamivudine  for 
HBV  reactivation  in  patients  with  solid  tumor  cancers
8, 9, 12). 
Several  studies  in  patients  with  solid  tumors  have  suggested  the 
efficacy  of  preventive  lamivudine  treatment.  However,  these 
findings  were  based  on  the  results  from  patients  with  different 
tumor  types  and  chemotherapy  regimens
10, 11).  We  therefore 
sought  to  evaluate  the  frequency  and  risk  factors  for  HBV 
reactivation,  and  to  assess  the  necessity  of  prophylactic 
lamivudine,  in  breast  cancer  patients  receiving  adjuvant 
anthracycline  based  chemotherapy.  This  is  the  first  study  of  the 
frequency  of  hepatitis  and  its  outcome,  as  well  as  its  impact  on 
planned  chemotherapy,  in  HBsAg  seropositive  breast  cancer 
patients,  all  of  whom  were  receiving  adjuvant  anthracycline 
-containing  adjuvant  chemotherapy. 
In  our  previous  study,  we  evaluated  liver  function  abnor-
malities  during  adjuvant  AC  chemotherapy  in  178  patients  with 
breast  cancer.  Most  of  them  (97%)  were  HBsAg  negative.  We 
found  that  62  (35%)  had  abnormal  liver  function.  However,  only 
two  patients  (1%)  developed  hepatic  dysfunction,  severe  enough 
to  fit  the  criteria  for  the  diagnosis  of  acute  hepatitis  while  on 
chemotherapy
20).  In  this  retrospective  evaluation  of  HBsAg 
positive  patients,  we  found  that  60%  of  the  patients  developed 
hepatic  dysfunction,  with  33%  meeting  the  criteria  for  the 
diagnosis  of  acute  hepatitis.  The  incidence  of  hepatitis  due  to 
HBV  reactivation  was  as  high  as  21%  of  all  patients.  Among 
them,  more  than  half  had  severe  icteric  hepatitis.  This  result  is 
consistent  with  several  previous  studies  that  reported  a  24～
28%  incidence  of  HBV  reactivation;  although  the  patients  and 
chemotherapeutic  regimens  differed
11, 21). 
Several  investigators  have  proposed  prophylactic  treatment 
with  lamivudine  in  patients  with  solid  tumor  cancers  based  on  the 
improved  outcomes  compared  to  a  historical  control  group
10, 11).  In 
a  small  study  on  breast  cancer,  it  was  reported  that  the  patients 
in  a  prophylactic  lamivudine  group  had  a  significantly  lower 
incidence  of  hepatitis  (12.9%  vs.  59.0%),  a  lower  HBV  reactiva-
tion  (6.5%  vs.  31.1%)  and  reduced  disruption  of  chemotherapy 
(16.1%  vs.  45.9%)  compared  with  a  control  group
22).  Although 
there  is  no  consensus  on  the  optimal  duration  of  prophylactic 
lamivudine  therapy,  some  have  recommended  that  lamivudine 
be  continued  until  at  least  6  weeks  after  the  end  of 
chemotherapy  based  on  previous  reports  of  withdrawal  flare- 
ups  of  hepatic  dysfunction
12).
Our  patients  were  treated  with  lamivudine  after  viral 
reactivation  was  detected.  However,  despite  lamivudine 
treatment,  improvement  of  the  liver  function  was  slow  and 
consequently,  chemotherapy  could  not  be  given  as  planned  in 
78%  of  these  patients,  which  was  16%  of  all  111  patients. 
Adjuvant  therapy  is  essential  for  most  patients  with  breast 
cancer.  Anthracycline-based  adjuvant  chemotherapy  is  asso-
ciated  with  an  11%  reduction  in  the  annual  odds  of  relapse  and 
a  16%  reduction  in  the  annual  odds  of  dying
23).  In  addition,  it  is 
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better  relapse  free  survival
24, 25).  Although  we  have  not  analyzed 
the  clinical  outcome  for  cancer,  because  of  the  relatively  short 
period  of  follow-up,  it  is  likely  that  incomplete  chemotherapy 
could  affect  the  outcome. 
For  the  14  patients  with  hepatitis  of  undetermined  cause,  we 
could  not  identify  the  disease  etiology  in  this  retrospective  study. 
There  are  several  potential  causes  such  as  another  virus,  drugs 
or  alternative  agents.  Another  possibility  is  that  some  HBV 
reactivation  might  not  have  been  detected  due  to  the  timing  of 
the  testing.  There  were  eight  patients  with  their  HBV  DNA 
tested  after  their  ALT  was  ≥grade  3.  It  is  well  known  that  viral 
replication  precedes  the  biochemical  flare-up.  Therefore,  by  the 
time  clinical  hepatitis  was  evident,  the  HBV  DNA  might  have 
decreased  to  undetectable  levels
6, 26).  Serial  HBV  DNA  follow-up 
has  been  shown  to  detect  HBV  reactivation  more  frequently 
than  conventional  monitoring
27).  In  addition,  the  method  used  to 
measure  HBV  DNA  is  important;  real-time  PCR  is  a  more 
sensitive  method,  with  a  detection  limit  of  4×10
2  copies/mL
18).  If 
we  had  tested  the  viral  DNA  serially,  from  the  beginning  of 
chemotherapy  with  real-time  PCR,  we  might  have  been  able  to 
detect  more  cases  of  hepatitis  associated  with  viral  reactivation. 
Finally,  we  failed  to  detect  any  clinical  factors  to  predict  HBV 
reactivation  during  chemotherapy.  Previously,  the  baseline  ALT 
level,  the  HBV  DNA  load,  the  use  of  anthracycline-containing 
regimens,  and  the  use  of  corticosteroids  were  reported  to  be 
risk  factors  for  HBV  reactivation
21, 28, 29).  The  univariate  analysis 
showed  that  older  patients  and  those  with  abnormal 
sonographic  findings  (fatty  liver/cirrhotic  change)  had  a  greater 
tendency  for  HBV  reactivation.  However,  the  multivariate 
analysis  identified  no  clinical  factors  that  could  predict  HBV 
reactivation  during  chemotherapy.  Even  the  steroid  treatment 
was  not  found  to  be  a  significant  factor;  this  might  have  been 
because  the  patients  received  steroid  medications  for  only  a 
short  time  per  each  cycle  as  an  antiemetic. 
Our  study  has  the  limitation  of  being  a  retrospective  study.  In 
addition,  we  did  not  regularly  perform  other  pertinent 
examinations,  including  serial  tests  for  HBV  DNA  and  liver 
ultrasonography.  In  addition,  detailed  investigations  of  other 
medications  and  alternative  agents  were  not  available,  and  they 
may  have  been  helpful  in  revealing  the  etiology  of  some  of  the 
cases  with  hepatitis  of  unknown  etiology.  Despite  these 
limitations,  our  study  clearly  showed  that  hepatitis  from  HBV 
reactivation  occurs  in  a  significant  proportion  of  patients  with 
HBsAg,  and  once  hepatitis  developed,  the  planned  chemotherapy 
had  to  be  disrupted  in  most  cases  even  with  lamivudine 
treatment.  Our  findings  suggest  that,  to  proceed  with  adjuvant 
chemotherapy  as  planned  in  HBsAg  positive  patients,  prevention 
of  HBV  reactivation  should  be  considered  rather  than  initiating 
the  treatment  after  hepatitis  has  already  developed.  However, 
prospective  randomized  clinical  trials  are  required  to  determine 
whether  preventive  treatment  would  be  more  effective  and 
determine  other  important  factors  such  as  the  associated  cost.. 
In  conclusion,  HBV  reactivation  occurred  in  breast  cancer 
patients  receiving  adjuvant  chemotherapy;  more  than  20%  of 
patients  who  were  inactive  HBsAg  carriers  developed  hepatitis 
due  to  viral  reactivation.  Most  of  the  affected  patients  had 
severe  hepatitis  and  this  resulted  in  either  a  delay  or  early 
termination  of  chemotherapy.  Considering  that  16%  of  HBsAg 
positive  patients  could  not  finish  chemotherapy  as  scheduled, 
even  when  lamivudine  was  used  for  treatment  after  detection  of 
the  viral  reactivation,  the  option  of  prophylactic  lamivudine 
should  be  considered  even  in  the  absence  of  prospective 
randomized  studies. 
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